Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on HSIC shares. The Goldman Sachs Group lowered Henry Schein from a "buy" rating to a "neutral" rating and decreased their target price for the company from $93.00 to $85.00 in a research report on Thursday, July 21st. Evercore ISI reduced their price target on Henry Schein to $83.00 in a research report on Tuesday, August 9th. William Blair reissued a "market perform" rating on shares of Henry Schein in a research report on Tuesday, May 3rd. StockNews.com lowered Henry Schein from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, July 19th. Finally, Stifel Nicolaus reduced their price target on Henry Schein from $90.00 to $80.00 in a research report on Friday, June 17th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $85.89.
Henry Schein Stock Down 1.5 %
Shares of HSIC opened at $76.45 on Wednesday. Henry Schein has a 52 week low of $70.25 and a 52 week high of $92.68. The company has a quick ratio of 0.95, a current ratio of 1.83 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $10.41 billion, a price-to-earnings ratio of 16.41, a PEG ratio of 2.09 and a beta of 0.75. The stock's 50-day moving average price is $76.81 and its 200-day moving average price is $82.13.
Henry Schein (NASDAQ:HSIC - Get Rating) last issued its earnings results on Tuesday, August 2nd. The company reported $1.16 EPS for the quarter, hitting analysts' consensus estimates of $1.16. Henry Schein had a return on equity of 15.56% and a net margin of 5.11%. The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.12 billion. During the same quarter in the prior year, the business earned $1.11 earnings per share. The company's revenue was up 2.1% compared to the same quarter last year. On average, sell-side analysts predict that Henry Schein will post 4.85 EPS for the current year.
Insider Buying and Selling
In related news, EVP Gerald A. Benjamin sold 11,489 shares of the company's stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $85.47, for a total value of $981,964.83. Following the completion of the transaction, the executive vice president now owns 95,616 shares of the company's stock, valued at approximately $8,172,299.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.00% of the stock is currently owned by insiders.